After FDA’s Policy Shift on Artificial Colors, State Enforcement and Private Litigation Risks Linger (JSON)

lexblog.com/lib/CMYCD9R8view recordjson

{
    "@context": "https://schema.org",
    "@type": "Article",
    "headline": "After FDA’s Policy Shift on Artificial Colors, State Enforcement and Private Litigation Risks Linger",
    "url": "https://www.lexblog.com/2026/02/16/after-fdas-policy-shift-on-artificial-colors-state-enforcement-and-private-litigation-risks-linger/",
    "identifier": {
        "@type": "PropertyValue",
        "name": "LexBlog Library record",
        "value": "LEX-WK-CMYCD9R8",
        "url": "https://www.lexblog.com/lib/CMYCD9R8/"
    },
    "datePublished": "2026-02-16T12:17:05-05:00",
    "dateModified": "2026-02-16T12:17:05-05:00",
    "author": {
        "@type": "Person",
        "name": "Matthew Berns, Namrata Kang"
    },
    "sourceOrganization": {
        "@type": "Organization",
        "name": "Troutman Pepper Locke"
    },
    "organizationScope": "at-publication",
    "isPartOf": "Regulatory Oversight",
    "about": "Administrative and Regulatory · Food, Drug & Agriculture · Health Care and Life Sciences",
    "sourceUrl": "https://www.regulatoryoversight.com/?p=22485",
    "sourceStability": "may-move"
}